Predictive Oncology Inc (POAI)

[77Port]

Hate them for their arrogance and lack of transparency. But they're a dog trying to catch the fox and they're on the scent. Or maybe they're trying to catch the shuttle to the moon because they are touching one of the sweet spots of the future. Today's report:
Predictive Oncology’s Wholly Owned Subsidiary Helomics completes integration of Quantitative Medicine

Source: GlobeNewswire Inc.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (QM) novel active-learning Computational Research Engine (CoRE™) with Helomics’ proprietary TumorSpace™ knowledgebase of 150,000 tumor drug response profiles and the TruTumor™ patient primary tumor cell line assay. This integration allows Helomics to offer a revolutionary new AI-driven patient-centric drug discovery service to Pharmaceutical companies that will significantly improve the chances of successfully translating new drugs into the clinic.
“With the completion of the CoRE integration, we are now able to offer our new PeDAL™ (Patient-cEntric Discovery by Active Learning) service to Pharmaceutical companies to allow patient-centric de-risking of compounds early in discovery, resulting in better prioritization of compounds and better coverage of patient diversity. This will dramatically improve the chances of successfully translating discoveries into the clinic, resulting in lowered costs, shortened timelines, and most importantly enhanced "speed-to-patient" for new therapies,” explained Dr. Carl Schwartz, Predictive Oncology, CEO. “We expect to see revenue generating projects that use PeDAL and CoRE in the first half of 2021,” commented Dr. Schwartz